NeuroSearch's toxicology issue

NeuroSearch A/S expects that its suspended Phase II trial of NS2389 (GW650250A) to treat depression, will be back on track within six months after further preclinical toxicology studies.

NeuroSearch (CSE:NEUS, Ballerup, Denmark) and partner Glaxo Wellcome plc (LSE:GLXO; GLX, London, U.K.) last week announced they had suspended the trial after finding side effects in animal toxicology studies that match previously seen side effects, but for which they cannot yet show the mechanism is the same. ...